

## Prof. Dr. BELGİN SÜSLEYİCİ

### Kişisel Bilgiler

**Fax Telefonu:** [+90 +90 535 291 3319](tel:+90+905352913319)

**E-posta:** [belgin.susleyici@marmara.edu.tr](mailto:belgin.susleyici@marmara.edu.tr)

**Diğer E-posta:** [belginsusleyici@gmail.com](mailto:belginsusleyici@gmail.com)

**Web:** <https://avesis.marmara.edu.tr/belgin.susleyici>

### Uluslararası Araştırmacı ID'leri

ScholarID: EEMk6jgAAAAJ

ORCID: 0000-0001-5790-4674

Publons / Web Of Science ResearcherID: JYO-9065-2024

ScopusID: 6602894847

Yoksis Araştırmacı ID: 9812

### Biyografi

Prof. Dr. Belgin SÜSLEYİCİ was born in 11. 10.1969 İstanbul/Turkey and completed her primary education in WestGreen Primary School, London while her father was a Military Attache in London,UK. Prof. Dr. SÜSLEYİCİ completed her undergraduate education at İstanbul University, Department of Biology-Molecular Genetics, her master's degree at Marmara University Faculty of Medicine, Department of Clinical Biochemistry, and her doctorate at Istanbul University Cerrahpaşa Faculty of Medicine, Department of Medical Biology. Prof. Dr. SÜSLEYİCİ completed her post-doc at the "Center for Preventive Medicine" in Nancy, France, with the International Federation of Clinical Chemistry (IFCC) Scholarship. Dr. SÜSLEYİCİ received her Associate Professor academic title from Cerrahpaşa Faculty of Medicine Medical Biology Department in 2003. Currently she is Full-time faculty member at Marmara University Faculty of Science, Division of Biology, Department of Molecular Biology, since 2007. Prof. Dr. Belgin SÜSLEYİCİ is currently continuing her responsibilities at Marmara University as Departmental Erasmus Coordinator, Director of Marmara University Environmental Problems Application and Research Center (Aug 2015- September 2023, Director of Marmara University Molecular Metabolism Research Laboratory and Pharmacogenetics Service Unit, Founder and President of Turkish Pharmacogenomics and Personalized Therapy Society (TSPPT), ESPT (European Society for Pharmacogenetics and Personalized Therapy) member, Eu-PIC (European Pharmacogenetics Implementation Consortium) Research and Diagnostic Board member, IFSO (International Federation for Metabolic Diseases and Surgery for Obesity) International Scientific Advisory Committee Member), IFSO Integrated Health Committee Member, Vascular Endothelial Growth Factor European Genomic Federation (VEGF) Consortium Board Member, European Union Commission Research and Innovation Specialist, TOSS (Turkish Obesity Surgery Association) Board Member and Scientific Committee Chairman, Co-founder and CEO, Chairman of the Board of Gene-IST Molecular Genetic Medicine, R&D and Consultancy Services Ltd.

Having completed many international and national research projects, Prof. Dr. Belgin SÜSLEYİCİ's main scientific research areas include individualized genetic-based drug treatments (pharmacogenetics), metabolomics, transcriptomics, nutrigenomics and translational research on the molecular basis of chronic diseases (cancer/cardiovascular/psychiatric), primary cell culture studies on aging and investigation of molecular mechanisms for chronic disease, and the production of diagnostic-prognostic kits to determine individual specific drug responses. Prof. SÜSLEYİCİ has organized and chaired many National and International congresses and courses.

Prof. Dr. Belgin SÜSLEYİCİ is the Editor of Trakya University Journal of Natural Sciences (TUJNS); Member of the Editorial Board of Jacobs Journal of Obesity and Chronicals and Obesity Diagnosis and Treatment; She continues to work as a scientific editor consultant in Diabetes Science Türkiye Klinikleri Journal of Pediatrics, Hippocrates Cardiology, Frontiers in Nutrition, Trends in Endocrinology, Istanbul Bilim University Florence Nightingale Journal of Medicine and

Turkiye Klinikleri Journal of Medical Sciences. She is a member of different scientific societies such as; Turkish Biochemistry Society, Society of Biology, Vascular and Molecular Cardiology Association, International Federation of Metabolic Diseases and Obesity Surgery (IFSO), International Federation of Societies for Histochemistry and Cytochemistry, Medical Biology Association, ESPT (European Society for Pharmacogenomics and Personalized Therapy). Prof. Dr. Belgin SÜSLEYİCİ has been a reviewer in high impact factor journals such as Molecular Medicine, Molecular Pharmacology, Cell and Pharmacogenetics, and she maintains her current positions as scientific board member in reputable international journals.

Prof. Dr. Belgin SÜSLEYİCİ has been continuing her studies in the field of Omics technologies, research of molecular causes of chronic diseases and Pharmacogenomics since 2000. Prof. Dr. Belgin SÜSLEYİCİ has 67 original research articles, 24 review articles, 130 international symposium summaries in Web of Science indexed journals. She has approx. 450 citations. She gave more than 50 international speeches/conferences upon invitation.

Dr. Súsleyici is and experienced well known scientist having completed numerous national international projects with high grants, high number of peer reviewed articles related to pharmacogenomics, disease molecular mechanisms, translational research, and an esteemed researcher owning a company located in technopark working for diagnostic/prognostic PGx kit production for personalized estimation of novel immunotherapeutic responses. She has supervised 24 MSc., PhD, and Post-Doc students in different scientific innovative topics mainly on individualized drug response for chronic diseases. She speaks fluent English, intermediate level of German and French.

## **Eğitim Bilgileri**

Doktora, İstanbul Üniversitesi, İstanbul Tıp Fakültesi, Temel Tıp Bilimleri Bölümü, Türkiye 1996 - 2000  
Yüksek Lisans, Marmara Üniversitesi, Fen Bilimleri Enstitüsü, Biyokimya (YI) (Tezli), Türkiye 1992 - 1995  
Lisans, İstanbul Üniversitesi, Fen Fakültesi, Biyoloji Bölümü, Türkiye 1986 - 1991

## **Yabancı Diller**

İngilizce, C1 İleri

## **Araştırma Alanları**

Moleküler Biyoloji ve Genetik, Genetik Bozuklukların Moleküler Biyolojisi, Genetik Mühendisliği, Kanser Moleküler Biyolojisi, Temel Bilimler

## **Akademik Unvanlar / Görevler**

Prof. Dr., Marmara Üniversitesi, Fen - Edebiyat Fakültesi, Biyoloji Bölümü, 2012 - Devam Ediyor  
Doç. Dr., Marmara Üniversitesi, Fen - Edebiyat Fakültesi, Biyoloji Bölümü, 2008 - 2012  
Doç. Dr., İstanbul Bilim Üniversitesi, Tıp Fakültesi, Temel Tıp Bilimleri Bölümü, 2005 - 2008  
Yrd. Doç. Dr., Kadir Has Üniversitesi, Sağlık Bilimleri Enstitüsü, Tıbbi Biyoloji Ve Genetik (YI) (Tezli), 2003 - 2005  
Öğretim Görevlisi, Kadir Has Üniversitesi, Sağlık Bilimleri Enstitüsü, Tıbbi Biyoloji Ve Genetik (YI) (Tezli), 2000 - 2003  
Araştırma Görevlisi, İstanbul Üniversitesi, Cerrahpaşa Tıp Fakültesi, Tıbbi Biyolojik Bilimler Bölümü, 1998 - 2000

## **Akademik İdari Deneyim**

Marmara Üniversitesi, Fen - Edebiyat Fakültesi, Biyoloji Bölümü, 2015 - Devam Ediyor  
Merkez Müdürü, Marmara Üniversitesi, Rektörlük, Çevre Sorunları Uygulama Ve Araştırma Merkezi, 2015 - 2023

Bölüm Akademik Teşvik Değerlendirme Komisyonu Başkanı, Marmara Üniversitesi, Fen Fakültesi, Biyoloji Bölümü, 2018 - 2020

Anabilim/Bilim Dalı Başkanı, İstanbul Bilim Üniversitesi, Tıp Fakültesi, Temel Tıp Bilimleri, 2006 - 2008

Anabilim/Bilim Dalı Başkanı, Kadir Has Üniversitesi, Tıp Fakültesi, Temel Tıp Bilimleri, 2002 - 2006

## Verdiği Dersler

İleri Moleküler Araştırma Teknikleri , Yüksek Lisans, 2023 - 2024

Moleküler Tanı Tekniklerinin Uygulamaları II , Doktora, 2023 - 2024

Genotip-Fenotip İlişkisinin İncelenmesi II, Doktora, 2023 - 2024

Metabolomikte Güncel Konular, Doktora, 2023 - 2024

Biyokimya 1, Lisans, 2023 - 2024

Biyomolekülleri Ayrımlama ve Saflaştırma Teknikleri, Yüksek Lisans, 2023 - 2024

İnsan Genetiği, Lisans, 2023 - 2024

Moleküler Hücre Biyolojisi-II , Lisans, 2023 - 2024

Gen Mühendisliği ve Biyoteknoloji I, Doktora, 2023 - 2024

Gen Mühendisliği ve Biyoteknoloji II, Doktora, 2023 - 2024

Kök Hücre Biyolojisi, Doktora, 2023 - 2024

Kanserin Moleküler Biyolojisi, Yüksek Lisans, 2023 - 2024

Genetik Mühendisliği, Lisans, 2023 - 2024

## Yönetilen Tezler

SÜSLEYİCİ B., Klopidoğrel kullanan hastalarda CYP2c19 geni RS4986893 polimorfizminin klinik kardiyovasküler olaylar ile ilişkisinin araştırılması, Yüksek Lisans, M.Ülker(Öğrenci), 2019

SÜSLEYİCİ B., Klopidoğrel'in membran bütünlüğüne olan etkisinin aml12 hepatosit hücre soyunda araştırılması, Yüksek Lisans, D.Kutlu(Öğrenci), 2019

SÜSLEYİCİ B., Klopidoğrel kullanan hastalarda CYP2c19 geni RS4244285 polimorfizminin klinik kardiyovasküler olaylar ile ilişkisinin araştırılması, Yüksek Lisans, Ö.Çatmaz(Öğrenci), 2019

SÜSLEYİCİ B., Varfarin farmakogenetiğinin kardiyovasküler hastalıkta incelenmesi, Yüksek Lisans, K.Bezci(Öğrenci), 2019

SÜSLEYİCİ B., Aml12 hepatosit hücre soyunda klopidoğrel'in mitokondriyal aktiviteye olan etkisinin araştırılması, Yüksek Lisans, M.Cahide(Öğrenci), 2019

SÜSLEYİCİ B., Koroner arter hastalarında statin farmakogenetiği, Yüksek Lisans, E.Gezer(Öğrenci), 2019

SÜSLEYİCİ B., Aml12 hepatosit hücre soyunda klopidoğrel'in lizozomal aktiviteye olan etkisinin araştırılması, Yüksek Lisans, E.Çarpar(Öğrenci), 2019

SÜSLEYİCİ B., Adiposit, hepatosit hücre soyları ve kokültürlerinde klopidoğrelin; CD68 gen anlatımı ve DNA hasarı üzerine etkilerinin incelenmesi, Yüksek Lisans, E.Bayar(Öğrenci), 2018

SÜSLEYİCİ B., Glipizidin adipositlerde glikoz hemostazı ve dna hasarına etkilerinin moleküler seviyede araştırılması, Yüksek Lisans, S.Çaker(Öğrenci), 2018

SÜSLEYİCİ B., Obezitede ran geni anlatımının adipogenez ile ilişkisinin araştırılması, Yüksek Lisans, S.Banu(Öğrenci), 2017

SÜSLEYİCİ B., İnsüline bağımlı olmayan Diabetes Mellitus'lu hastalarda endotelial nitrik oksid sentaz (eNOS) Glu298Asp polimorfizminin araştırılması, Yüksek Lisans, B.BAYOĞLU(Öğrenci), 2007

SÜSLEYİCİ B., Akut koroner sendrom ve kronik koroner arter hastalarında endotelial nitrik oksit sentetaz (e NOS) Glu 298-Asp polimorfizminin klinik ve biyokimyasal etkilerinin araştırılması, Yüksek Lisans, Y.ÇEBİ(Öğrenci), 2006

SÜSLEYİCİ B., Akut koroner sendrom ve kronik koroner arter hastalarında endotelial nitrik oksid sentaz (enos) t-786c polimorfizminin klinik ve biyokimyasal etkilerinin araştırılması, Yüksek Lisans, S.MELİL(Öğrenci), 2006

SÜSLEYİCİ B., Azospermili, oligozoospermili ve normozoospermili erkeklerde Y kromozomu mikrodelsyonlarının polimeraz zincir reaksiyonu ile araştırılması, Yüksek Lisans, M.ULUĞ(Öğrenci), 2004

SÜSLEYİCİ B., Türk toplumunda apolipoprotein B geni EcoRI polimorfizminin aterosklerotik hastalarda ve sağlıklı kişilerde araştırılması, Yüksek Lisans, A.VERTİİ(Öğrenci), 2003

SÜSLEYİCİ B., İskemik kalp hastalarında homosistein ve metilentetrahidrofolat redüktaz (MTHFR) enzimi gen polimorfizminin rolü, Yüksek Lisans, E.DAK(Öğrenci), 2003

## SCI, SSCI ve AHCI İndekslerine Giren Dergilerde Yayınlanan Makaleler

- I. **The 10th Santorini conference: Systems medicine, personalised health and therapy. "The odyssey from hope to practice: Patient first. Keep Ithaca always in your mind", Santorini, Greece, 23–26 May 2022**  
Visvikis-Siest S., Stathopoulou M. G., Sunder-Plassmann R., Alizadeh B. Z., Barouki R., Chatzaki E., Dagher G., Dedoussis G., Deloukas P., Haliassos A., et al.  
Frontiers in Genetics, cilt.14, 2023 (SCI-Expanded)
- II. **Investigation of DPYD, MTHFR and TYMS polymorphisms on 5-fluorouracil related toxicities in colorectal cancer**  
Cevik M., Namal E., Sener N. D., Koksal U. I., Cagatay P., Deliorman G., Ciftci C., KARAALP A., SÜSLEYİCİ B.  
PERSONALIZED MEDICINE, cilt.19, sa.5, ss.435-444, 2022 (SCI-Expanded)
- III. **Investigation of Vascular Endothelial Growth Factor Polymorphisms on Risk, Metastasis, Laterality, and Prognosis of Colorectal Cancer in Turkish Subjects**  
Cevik M., Namal E., Dinc-Sener N., Iner-Koksal U., Ciftci C., Susleyici B.  
GENETIC TESTING AND MOLECULAR BIOMARKERS, cilt.26, sa.5, ss.298-306, 2022 (SCI-Expanded)
- IV. **Association of PD-1 and PDL-1 gene polymorphisms with colorectal cancer risk and prognosis**  
Cevik M., Namal E., Iner-Koksal U., Dinc-Sener N., KARAALP A., Ciftci C., SÜSLEYİCİ B.  
MOLECULAR BIOLOGY REPORTS, cilt.49, sa.3, ss.1827-1836, 2022 (SCI-Expanded)
- V. **The effects of glipizide on DNA damage and nuclear transport in differentiated 3T3-L1 adipocytes**  
Cevik M., Caker S., Deliorman G., Cagatay P., KOLDEMİR GÜNDÜZ M., SÜSLEYİCİ B.  
MOLECULAR BIOLOGY REPORTS, cilt.49, ss.1151-1159, 2022 (SCI-Expanded)
- VI. **INVESTIGATION THE EFFECTS OF TREATMENT PLANTS ON HEAVY METAL LEVELS AND MUTAGENICITY OF WASTEWATERS**  
Dartan G., Cevik M., Aksu M. B., Can Z. S., Keskins Y., Yurdun T., Deliorman G., Süssleyici B.  
FRESENIUS ENVIRONMENTAL BULLETIN, cilt.31, sa.8B, ss.8952-8957, 2022 (SCI-Expanded)
- VII. **Alterations in niban gene expression as a response to stress conditions in 3T3-L1 adipocytes**  
Cevik M., KOLDEMİR GÜNDÜZ M., Deliorman G., SÜSLEYİCİ B.  
MOLECULAR BIOLOGY REPORTS, cilt.47, sa.12, ss.9399-9408, 2020 (SCI-Expanded)
- VIII. **Evaluation of Cytotoxicity and Mutagenicity of Wastewater from Istanbul: Data from Hospitals and Advanced Wastewater Treatment Plant**  
Cevik M., DARTAN G., Ulker M., Bezci K., Deliorman G., Cagatay P., LAÇİN T., CİNEL İ. H., Aksu B., KESKİN Y., et al.  
BULLETIN OF ENVIRONMENTAL CONTAMINATION AND TOXICOLOGY, cilt.104, sa.6, ss.852-857, 2020 (SCI-Expanded)
- IX. **Association of Sweet Taste Receptor Gene Polymorphisms with Dental Caries Experience in School Children**  
HAZNEDAROĞLU E., Koldemir-Gunduz M., Bakir-Coskun N., Bozkus H. M., Cagatay P., Susleyici-Duman B., Menten A.  
CARIES RESEARCH, cilt.49, sa.3, ss.275-281, 2015 (SCI-Expanded)
- X. **11 beta-hydroxysteroid dehydrogenase type 1 gene expression is increased in ascending aorta tissue of metabolic syndrome patients with coronary artery disease**  
Atalar F., Vural B., Ciftci C., Demirkan A., Akan G., Susleyici-Duman B., Gunay D., Akpınar B., Sagbas E., Ozbek U., et al.  
GENETICS AND MOLECULAR RESEARCH, cilt.11, sa.3, ss.3122-3132, 2012 (SCI-Expanded)
- XI. **FTO mRNA Expression in Extremely Obese and Type 2 Diabetic Human Omental and Subcutaneous Adipose Tissues**  
Susleyici-Duman B., Zengin K., KAYHAN F. E., Koldemir M., Dagistanli F. K., Cagatay P., Ozturk M., Taskin M.

OBESITY SURGERY, cilt.21, sa.11, ss.1766-1773, 2011 (SCI-Expanded)

- XII. **Heat Shock Protein Genes in Fish**  
KAYHAN F. E., Duman B.  
TURKISH JOURNAL OF FISHERIES AND AQUATIC SCIENCES, cilt.10, sa.2, ss.287-293, 2010 (SCI-Expanded)
- XIII. **Genetics of obesity: Medical education Obezite Genetiği**  
Süsleyici Duman B., KAYHAN F. E., Sesal C.  
Turkiye Klinikleri Journal of Medical Sciences, cilt.29, sa.2, ss.520-525, 2009 (SCI-Expanded)
- XIV. **Presence of fatty-acid-binding protein 4 expression in human epicardial adipose tissue in metabolic syndrome**  
Vural B., Atalar F., Ciftci C., Demirkan A., Susleyici-Duman B., Gunay D., Akpinar B., Sagbas E., Ozbek U., Buyukdevrim A. S.  
CARDIOVASCULAR PATHOLOGY, cilt.17, sa.6, ss.392-398, 2008 (SCI-Expanded)
- XV. **Common Variants in the ATP-binding Cassette Transporter 1 Gene with Decreased HDL-Cholesterol Levels and Coronary Artery Disease**  
Catakoglu A. B., Duman B., Kurtoglu H., ERSÖZ M., Sener M., Celebi H., ÇAĞATAY P., Aytekin V., Aytekin S.  
ARCHIVES OF MEDICAL RESEARCH, cilt.39, sa.8, ss.735-742, 2008 (SCI-Expanded)
- XVI. **Association of endothelial nitric oxide synthase promoter region (T-786C) gene polymorphism with acute coronary syndrome and coronary heart disease**  
Ciftci C., Melil S., Cebi Y., Ersoz M., Cagatay P., Kilicgedik M., Duman B.  
LIPIDS IN HEALTH AND DISEASE, cilt.7, 2008 (SCI-Expanded)
- XVII. **Lipoprotein lipase gene PvuII polymorphism serum lipids and risk for coronary artery disease: Meta-analysis**  
Cagatay P., Susleyici-Duman B., Ciftci C.  
DISEASE MARKERS, cilt.23, sa.3, ss.161-166, 2007 (SCI-Expanded)
- XVIII. **Apolipoprotein B gene variants are involved in the determination of blood glucose and lipid levels in patients with non-insulin dependent diabetes mellitus**  
Duman B., ÖZTÜRK SEZGİN M., Yilmazer S., Çağatay P., Hatemi H.  
Cell Biochemistry and Function, cilt.24, sa.3, ss.261-267, 2006 (SCI-Expanded)
- XIX. **DNA polymorphism of Pvu II site in the lipoprotein lipase gene in patients with non-insulin dependent diabetes mellitus**  
Duman B., Ozturk M., Yilmazer S., Cagatay P., Hatemi H.  
CELL BIOCHEMISTRY AND FUNCTION, cilt.23, sa.6, ss.399-404, 2005 (SCI-Expanded)
- XX. **Protective effects of a calcium channel blocker on apoptosis in thymus of neonatal STZ-diabetic rats**  
Dağistanlı F. K., Duman B., ÖZTÜRK SEZGİN M.  
Acta Histochemica, cilt.107, sa.3, ss.207-214, 2005 (SCI-Expanded)
- XXI. **Genetic variations of the apolipoprotein B gene in Turkish patients with coronary artery disease**  
Duman B., Turkoglu C., Akpinar B., Guden M., Vertii A., Cagatay P., Gunay D., Buyukdevrim A.  
ANNALS OF HUMAN BIOLOGY, cilt.32, sa.5, ss.620-629, 2005 (SCI-Expanded)
- XXII. **Polymorphisms at the ligand binding site of the vitamin D receptor gene and osteomalacia**  
AK S., Kahraman H., DURSUN E., Duman B., Erensoy N., Alagöl F., Tanakol R., Yilmazer S.  
Disease Markers, cilt.21, sa.4, ss.191-197, 2005 (SCI-Expanded)
- XXIII. **Lipoprotein lipase gene polymorphism and lipid profile in coronary artery disease**  
Duman B., Türkoğlu Ç., Akpinar B., Guden M., Vertii A., Dak E., Çağatay P., Günay D., Büyükdevrim A. S.  
Archives of Pathology and Laboratory Medicine, cilt.128, sa.8, ss.869-874, 2004 (SCI-Expanded)
- XXIV. **Lack of association between vitamin D receptor gene polymorphism (BsmI) and osteomalacia**  
Kahraman H., Duman B., Alagöl F., Tanakol R., Yilmazer S.  
Journal of Bone and Mineral Metabolism, cilt.22, sa.1, ss.39-43, 2004 (SCI-Expanded)
- XXV. **Vitamin D receptor alleles, bone mineral density and turnover in postmenopausal osteoporotic and healthy women**  
Duman B., Tanakol R., Erensoy N., Ozturk M., Yilmazer S.  
MEDICAL PRINCIPLES AND PRACTICE, cilt.13, sa.5, ss.260-266, 2004 (SCI-Expanded)

- XXVI. **Thiols, malonaldehyde status in the Turkish and total antioxidant patients with type 2 diabetes mellitus**  
Duman B., Ozturk M., Yilmazer S., Hatemi H.  
TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, cilt.201, sa.3, ss.147-155, 2003 (SCI-Expanded)
- XXVII. **Effect of abdominal obesity on insulin resistance and the components of the metabolic syndrome: Evidence supporting obesity as the central feature**  
Turkoglu C., Duman B., Gunay D., Cagatay P., Ozcan R., Buyukdevrim A.  
OBESITY SURGERY, cilt.13, sa.5, ss.699-705, 2003 (SCI-Expanded)
- XXVIII. **The interrelationship between insulin secretion and action in Type 2 diabetes mellitus with different degrees of obesity: Evidence supporting central obesity**  
Susleyici Duman B., Turkoglu C., Gunay D., Cagatay P., Demiroglu C., Sevin Buyukdevrim A.  
Diabetes, Nutrition and Metabolism - Clinical and Experimental, cilt.16, sa.4, ss.243-250, 2003 (SCI-Expanded)

## **Diğer Dergilerde Yayınlanan Makaleler**

- I. **The effects of SNAI1 rs6125849 gene polymorphism on metastasis and survival in colorectal cancer: Preliminary results from Turkish subjects**  
Cevik M., Namal E., Sener N. D., Koksall U. I., Deliorman G., Ciftci C., SÜSLEYİCİ B.  
GENE REPORTS, cilt.24, 2021 (ESCI)
- II. **Prevalence of CYP2C19 Polymorphisms in Clopidogrel Treated Turkish Patients: Preliminary Results, 2017**  
SÜSLEYİCİ B., Ciftci C., Yurdakul S., Cevik M., Akdeniz C. S., Canbolat I. P., Deliorman G., KARAALP A.  
Current Pharmacogenomics and Personalized Medicine, cilt.18, sa.2, ss.116-122, 2021 (Scopus)
- III. **The effect of visfatin rs2110385 gene polymorphism over oral antidiabetic drug response**  
SÜSLEYİCİ DUMAN B., KOLDEMİR GÜNDÜZ M., KAYHAN F. E., ÇAĞATAY P., TAŞKIN M.  
Annals of Medical Research, cilt.28, sa.12, ss.2134, 2021 (Hakemli Dergi)
- IV. **DNA Damage in AML-12 Hepatocytes and 3T3-L1 Adipocytes Treated with Clopidogrel**  
Bayar E., Cevik M., Caker S., Cagatay P., SÜSLEYİCİ B.  
CURRENT DRUG SAFETY, cilt.16, sa.3, ss.252-258, 2021 (ESCI)
- V. **The effects of CYP2C9 and VKORC1 gene polymorphisms on warfarin maintenance dose in Turkish cardiac patients**  
AKDENİZ C. S., ÇEVİK M., CANBOLAT İ. P., YURDAKUL S., ÇAĞATAY P., ÇİFTÇİ Ç., KARAALP A., SÜSLEYİCİ DUMAN B.  
FUTURE CARDIOLOGY, cilt.16, ss.645-654, 2020 (ESCI)
- VI. **Warfarin pharmacogenetics in patients with heart valve replacement**  
Bezci K., Cevik M., Akdeniz C. S., Canbolat I. P., Yurdakul S., SÜNBÜL M., Atas H., Cagatay P., Ciftci C., KARAALP A., et al.  
GENE REPORTS, cilt.20, 2020 (ESCI)
- VII. **The effects of oral antidiabetics on adipogenesis related gene expressions in 3T3-L1, AML12 cell lines and their co-cultures**  
KOLDEMİR GÜNDÜZ M., Çevik M., ÇAĞATAY P., SÜSLEYİCİ DUMAN B.  
Eurasian J. Bio. Chem. Sci, cilt.2, sa.1, ss.29-37, 2019 (Hakemli Dergi)
- VIII. **Esansiyel Hipertansiyonda Bradikinin B Reseptör Geni C-58T Polimorfizminin Total-Kolesterol ve Kan Şekeri Üzerine Etkileri**  
SÜSLEYİCİ DUMAN B., KOLDEMİR GÜNDÜZ M., ZENGİN S. Ü., ÇAĞATAY P., BOZKUŞ H. M., BAKIR N., TAŞKIN M.  
Bezmiâlem Science, cilt.5, sa.1, ss.7-15, 2017 (Hakemli Dergi)
- IX. **Relationship of Bradykinin B-2 Receptor Gene C-58T Variation with Total-Cholesterol and Glucose in Essential Hypertension**  
SÜSLEYİCİ B., Gunduz M. K., Zengin S. U., Cagatay P., Bozkus H. M., Bakir N., Taskin M.  
BEZMIALEM SCIENCE, cilt.5, sa.1, ss.7-15, 2017 (ESCI)
- X. **Obezitede Ran Geni Anlatımının Adipogenez ile İlişkisinin Araştırılması**

DEMİR S. B., KOLDEMİR GÜNDÜZ M., ÇEVİK M., ÇİFTÇİ Ç., SÜSLEYİCİ DUMAN B.

İSTANBUL BİLİM ÜNİVERSİTESİ FLORENCE NIGHTINGALE TIP DERGİSİ, cilt.2, sa.3, ss.201-207, 2016 (Hakemli Dergi)

- XI. **Association of Sweet Taste Sensitivity and Caries Experience with BMI and Hedonic Responses**  
HAZNEDAROĞLU E., SÜSLEYİCİ DUMAN B., KOLDEMİR GÜNDÜZ M., ÇAĞATAY P., BAKIR N., BOZKUŞ H. M., EREN GİRAY F., MENTEŞ A. R.  
Gavin Journal of Dental Sciences, sa.2016, ss.8-14, 2016 (Hakemli Dergi)
- XII. **Kişinin Genetik Yapısına Özel Bireysel İlaç Tedavileri Farmakogenetik**  
SÜSLEYİCİ DUMAN B.  
Yeni Türkiye Dergisi Bilim ve Teknoloji Özel Sayısı III, 2016 (Hakemli Dergi)
- XIII. **The Effects of Peroxiredoxin 6 Gene rs41055489 Variation on Oxidative Stress Mechanisms in Human Model Organism**  
Atasayar Ünver Z., KOLDEMİR GÜNDÜZ M., KAYHAN F. E., KAYMAK G., ZENGİN S. Ü., ÇAĞATAY P., SÜSLEYİCİ DUMAN B.  
BEZMIALEM SCIENCE, sa.3, ss.37-42, 2015 (Hakemli Dergi)
- XIV. **Histopathological Effects of Fluoxetine on Zebra Fish Danio Rerio Gills**  
YÖN ERTUĞ N. D., AKBULUT C., ALSARAN M., ÖZTÜRK B., KAYHAN F. E., KAYMAK G., SÜSLEYİCİ DUMAN B.  
Elixir Applied Zoology, cilt.89, ss.36709-36711, 2015 (Hakemli Dergi)
- XV. **The Effects of Peroxiredoxin 6 Gene rs41055498 Variation on Oxidative Stress Mechanisms in Human Model Organism**  
ATASAYAR ÜNVER Z., KOLDEMİR GÜNDÜZ M., KAYHAN F. E., KAYMAK G., ZENGİN S. Ü., ÇAĞATAY P., SÜSLEYİCİ DUMAN B.  
Bezmialem Science, 2015 (Hakemli Dergi)
- XVI. **Mangan süperoksit dismütaz Ala16Val gen polimorfizmlerinin koroner arter olaylarında koruyucu rollerinin araştırılması**  
ATMACA H., KOLDEMİR GÜNDÜZ M., ÇAĞATAY P., ÇEVİK M., SÜSLEYİCİ DUMAN B.  
FNG& Bilim Tıp Dergisi, cilt.1, sa.3, ss.134-144, 2015 (Hakemli Dergi)
- XVII. **Zebra balıklarında (Danio rerio) ağır metal indüksiyonunun oksidatif stres parametrelerine etkisi.**  
Kayhan F. E., Atasayar Ünver Z., Koldemir Gündüz M., Süsleyici B., Sesal N. C.  
Journal of Fisheries Sciences, cilt.8, sa.3, ss.199-207, 2014 (Hakemli Dergi)
- XVIII. **The relationship of Bradykinin B<sub>2</sub> receptor gene variation with obesity, hypertension and lipid variables in obese patients**  
Bakir N., Bozkuş H. M., KOLDEMİR GÜNDÜZ M., Çağatay P., Taşkın M., Süsleyici Duman B.  
Acta medica academica, cilt.43, sa.2, ss.144-154, 2014 (Scopus)
- XIX. **Prevalence of endothelial nitric oxide synthase E298D polymorphism in Turkish patients with essential hypertension**  
Kayhan F. E., Koldemir M., Çağatay P., Çiftçi P., Süsleyici Duman B.  
Diabetes and Metabolic Syndrome: Clinical Research and Reviews, cilt.7, sa.1, ss.12-16, 2013 (Scopus)
- XX. **Relationship of RIC-3 gene rs1528133 polymorphism with varying degrees of body weight and eating behavior.**  
Koldemir M., Kahveci C., Bayer H., Cagatay P., Yildiz S., Bagriacik N., Susleyici-Duman B.  
Diabetes & metabolic syndrome, cilt.6, sa.2, ss.90-95, 2012 (Scopus)
- XXI. **Relationship of transcription factor 7 like 2 gene rs7903146 variation with type 2 diabetes and obesity related parameters**  
Kahveci C., Koldemir M., Cagatay P., Bayer H., Yildiz S., Bagriacik N., Duman B.  
Diabetes and Metabolic Syndrome: Clinical Research and Reviews, cilt.6, sa.1, ss.48-53, 2012 (Scopus)
- XXII. **Tip 2 diabet ve obezitede gen ontoloji ve yolak analizleri ile ekspresyon profilinin irdelenmesi**  
SÜSLEYİCİ DUMAN B., KAYHAN F. E., SESAL N. C.  
Diabet Bilimi, 2009 (Hakemli Dergi)
- XXIII. **Association of resistin gene 3'-untranslated region EX4-44G→A polymorphism with obesity- and insulin-related phenotypes in Turkish type 2 diabetes patients**

Duman B., Çağatay P., Hatemi H., ÖZTÜRK SEZGİN M.  
Review of Diabetic Studies, cilt.4, sa.1, ss.49-55, 2007 (Scopus)

- XXIV. **The effects of phase II cardiac rehabilitation programme on patients undergone coronary bypass surgery Koroner baypas geçiren olgularda faz II kardiyak rehabilitasyon programının etkileri**  
Çiftçi Ç., Duman B., Çağatay P., Demiroğlu C., Aytekin V.  
Anadolu Kardiyoloji Dergisi, cilt.5, sa.2, ss.116-121, 2005 (Scopus)
- XXV. **Koroner baypas geçiren olgularda faz II kardiyak rehabilitasyon programının etkileri**  
ÇİFTÇİ Ç., SÜSLEYİCİ DUMAN B., ÇAĞATAY P., DEMİROĞLU C., AYTEKİN V.  
Anadolu Kardiyoloji Dergisi, cilt.5, ss.116-121, 2005 (Hakemli Dergi)
- XXVI. **Programmed cell death in heart failure: Review Programli hücre ölümünün kalp yetersizliği indeki yeri**  
Süsleyici Duman B., Türkoğlu Ç., ÖZTÜRK SEZGİN M.  
Turkiye Klinikleri Journal of Medical Sciences, cilt.25, sa.1, ss.85-92, 2005 (Scopus)

## Hakemli Kongre / Sempozyum Bildiri Kitaplarında Yer Alan Yayınlar

- I. **Relationship of Vitamin D Receptor Gene Polymorphisms with Adverse Drug Responses In Patients With Colorectal Cancer**  
Tosun M., ÇEVİK M., SÖNMEZ Ö., ER Ö., DEMİR O. G., OYAN ULUÇ B., GÜVEN MERT A., DELİORMAN G., KARAALP A., SÜSLEYİCİ DUMAN B.  
9th International Molecular Biology and Biotechnology Congress, 6 - 10 Aralık 2020
- II. **Tramadol: From CYP2D6 Pharmacogenetic Testing To Clinical Dat**  
ÇEVİK M., KARAALP A., GÜNDÜZ O. H., YAZICI G., ÇAĞATAY P., SÜSLEYİCİ DUMAN B.  
5th ESPT Congress Precision Medicine and Personalised Health, Sevilla, İspanya, 16 - 18 Ekim 2019
- III. **The Efficiency of PPI Use in Turkish Patients: CYP2C19 Pharmacogenetic Testing**  
SÜSLEYİCİ DUMAN B., ÇEVİK M., KARAALP A., YURDAKUL S., CANBOLAT İ. P., GÜNDÜZ O. H., YAZICI G., CEYHAN B., ÇAĞATAY P., ÇİFTÇİ Ç.  
5th ESPT Congress Precision Medicine and Personalised Health, 16 - 18 Ekim 2019
- IV. **Effects of oral antidiabetics on oxidative stress parameters in liver metabolism**  
KOLDEMİR GÜNDÜZ M., KAYMAK G., ÇEVİK M., ÇAĞATAY P., SÜSLEYİCİ DUMAN B.  
2nd International Eurasian Conference on Biological and Chemical Science, 28 - 29 Haziran 2019
- V. **The effects of oral antidiabetics on adipogenesis related gene expressions in 3T3-L1, AML12 cell lines and their co-cultures**  
KOLDEMİR GÜNDÜZ M., ÇEVİK M., ÇAĞATAY P., SÜSLEYİCİ DUMAN B.  
2nd International Eurasian Conference on Biological and Chemical Sciences, 28 - 29 Haziran 2019
- VI. **Implementation of Pharmacogenetics in Turkish Clinical Practice:Challenges and Opportunities**  
SÜSLEYİCİ DUMAN B.  
International Congress on Biological and Medical Sciences 2018, 31 Ekim - 03 Kasım 2018
- VII. **Implementation Of Pharmacogenetics In Turkish Clinical Practice: The Example Of Dihydropyrimidine Dehydrogenase**  
SÜSLEYİCİ DUMAN B.  
The 9 th Santorini Conference "Systems medicine and Personalised Health and Therapy": The Odyssey from Hope to Practice, Santorini, Yunanistan, 30 Eylül - 03 Ekim 2018
- VIII. **Pharmacogenetics Of Clopidogrel In Coronary Artery Disease Patients: Results From Turkish Clinical Practice**  
SÜSLEYİCİ DUMAN B., ÇİFTÇİ Ç., KARAALP A., ÇEVİK M., YURDAKUL S., CANBOLAT İ. P., GEZER E., BEZCİ K., ÇAĞATAY P., SCHAİK R. V.  
The 9th Santorini Conference Systems Medicine and Personalised Health Therapy « The Odyssey From Hope To Practice », Santorini, Yunanistan, 30 Eylül - 03 Ekim 2018
- IX. **Pharmacogenetics: Implementing Personalized Medicine in Turkish Clinical Practice**



SÜSLEYİCİ DUMAN B.

IV. International Congress on Applied Biological Sciences, 3 - 05 Mayıs 2018

- X. **Rational Drug Applications to Individuals Specific Genetic Structure:Pharmacogenetic**  
SÜSLEYİCİ DUMAN B.  
1st International Health Sciences Congress, 23 - 25 Kasım 2017
- XI. **The Effects of Glipizide and Acarbose on Obesity and Glucose Metabolism in 3T3-L1, AML12 cell lines and their co-cultures**  
KOLDEMİR GÜNDÜZ M., ÇEVİK M., ÇAĞATAY P., SÜSLEYİCİ DUMAN B.  
İVEK Uluslararası İlaç ve Eczacılık Kongresi, İstanbul, Türkiye, 26 - 29 Nisan 2017
- XII. **Role of genetics in the selection of surgical methods and its use as a primary treatment**  
SÜSLEYİCİ DUMAN B.  
Congress for the surgery of obesity and metabolic disorders, 12 - 15 Ekim 2017
- XIII. **Investigation Of The Effects Of Clopidogrel In AML12 Hepatocyte Cell Line Over Lysosomal Activity**  
ÇARPAR E., KARABAY M. C., KUTLU D., ÇEVİK M., SÜSLEYİCİ DUMAN B.  
5 th National amp 3 rd Mediterranean Congress for the Surgery of Obesity and Metabolic Disorders, Antalya, Türkiye, 12 - 15 Ekim 2017
- XIV. **The Effects of Clopidogrel on CD68 Gene Expression in Adipocyte, Hepatocyte Cell Lines and Co-cultures**  
BAYAR E., ÇEVİK M., ÇAKER S., SÜSLEYİCİ DUMAN B.  
5th National 3rd Mediterranean Congress for the Surgery of Obesity and Metabolic Disorders, Antalya, Türkiye, 12 - 15 Ekim 2017
- XV. **Investigation of the Effects of Clopidogrel in AML Hepatocyte Cell Line Over Membrane Integrity**  
KUTLU D., KARABAY M. C., ÇARPAR E., ÇEVİK M., SÜSLEYİCİ DUMAN B.  
5 th National amp 3 rd Mediterranean Congress for the Surgery of Obesity and Metabolic Disorders, Antalya, Türkiye, 12 - 15 Ekim 2017
- XVI. **Investigation Of The Effects Of Clopidogrel In AML12 Hepatocyte Cell Line Over Mitochondrial Activity. Mitochondrial Activity**  
KARABAY M. C., KUTLU D., ÇARPAR E., ÇEVİK M., SÜSLEYİCİ DUMAN B.  
5 th National amp 3 rd Mediterranean Congress for the Surgery of Obesity and Metabolic Disorders, Antalya, Türkiye, 12 - 15 Ekim 2017
- XVII. **Association Of CYP2C19 Gene rs4244285 Polymorphism With Clinical Cardiovascular Events In Patients Using Clopidogrel**  
ÇATMAZ Ö., ÇEVİK M., GEZER E., BEZCİ K., ÜLKER M., YURDAKUL S., ELÇİOĞLU CENGİZ B., CANBOLAT İ. P., KARAALP A., ÇİFTÇİ Ç., et al.  
4 th ESPT Conference. Pharmacogenomics and Personalised Medicine: research progress and clinical implementation, Catalunya, İspanya, 4 - 07 Ekim 2017
- XVIII. **Investigation Of CYP2C9 2 Polymorphism In Patients With Cardiovascular Disease Using Warfarin**  
BEZCİ K., ÇEVİK M., GEZER E., ÜLKER M., ÇATMAZ Ö., YURDAKUL S., ELÇİOĞLU CENGİZ B., CANBOLAT İ. P., KARAALP A., ÇİFTÇİ Ç., et al.  
4th ESPT Conference. Pharmacogenomics and Personalised Medicine: Research Progress and Clinical Implementation, Catalunya, İspanya, 4 - 07 Ekim 2017
- XIX. **The Effects of Clopidogrel on DNA damage in Adipocyte and Hepatocyte Cell Lines**  
BAYAR E., ÇEVİK M., ÇAKER S., SÜSLEYİCİ DUMAN B.  
4th ESPT Conference. Pharmacogenomics and Personalised Medicine: Research Progress and Clinical Implementation, Catalunya, İspanya, 4 - 07 Ekim 2017
- XX. **Genetic Polymorphisms of CYP3A4 1B In Patients With Coronary Artery Disease Using Statin**  
GEZER E., ÇEVİK M., BEZCİ K., ÜLKER M., ÇATMAZ Ö., YURDAKUL S., ELÇİOĞLU CENGİZ B., CANBOLAT İ. P., KARAALP A., ÇİFTÇİ Ç., et al.  
4th ESPT Conference. Pharmacogenomics and Personalised Medicine: Research Progress and Clinical Implementation, KATANYA, İtalya, 4 - 07 Ekim 2017
- XXI. **National drug applications to individual specific genetic structure:Pharmacogenetics**

SÜSLEYİCİ DUMAN B.

Innovation in medicine summit 3 in drug and biotechnology, 11 - 13 Mayıs 2017

- XXII. **Effects of metformin on oxidative stress parameters in 3T3-L1 adipocytes by iCELLigence system**  
GÜNDÜZ KOLDEMİR M., ÇEVİK M., ÇAĞATAY P., SÜSLEYİCİ DUMAN B.  
İVEK Uluslararası İlaç ve Eczacılık Kongresi, İstanbul, Türkiye, 26 - 29 Nisan 2017
- XXIII. **Glipizidin Adipositlerde Glikoz Hemostazı ve Programlı Hücre Ölümüne Etkilerinin Moleküler Seviyede Araştırılması**  
ÇAKER S., ÇEVİK M., KOLDEMİR GÜNDÜZ M., BAYAR E., SÜSLEYİCİ DUMAN B.  
İVEK Uluslararası İlaç ve Eczacılık Kongresi, İstanbul, Türkiye, 26 - 29 Nisan 2017
- XXIV. **The effect of glipizide and acarbose on obesity and glucose metabolism in 3T3-L1, AML12 cell lines and their co-cultures**  
KOLDEMİR GÜNDÜZ M., ÇEVİK M., ÇAĞATAY P., SÜSLEYİCİ DUMAN B.  
İVEK 3rd International Convention of Pharmaceuticals and Pharmacies, 26 - 29 Nisan 2017
- XXV. **Effect of metformin on oxidative stress parameters in 3T3-L1 adipocytes by iCELLigence system**  
KOLDEMİR GÜNDÜZ M., ÇEVİK M., ÇAĞATAY P., SÜSLEYİCİ DUMAN B.  
İVEK 3rd International Convention of Pharmaceuticals and Pharmacies, 26 - 29 Nisan 2017
- XXVI. **Farmakogenetiğin ve nütrigenetiğin obezite cerrahisindeki rolü ve gelecek/obezite cerrahisinde güncel farmakogenetik ve nütrigenetik yaklaşımlar**  
SÜSLEYİCİ DUMAN B.  
Cerrahpaşa cerrahi toplantıları-Türk obezite cerrahisi derneği 2.kış okulu, Türkiye, 27 - 28 Ocak 2017
- XXVII. **BARX1 is down regulated in children with non syndromicsupernumerary teeth**  
MENTEŞ A. R., PEKEL B., ÇEVİK M., KOLDEMİR GÜNDÜZ M., SÜSLEYİCİ DUMAN B.  
the Ninth International Symposium on Dental Enamel: "Enamel 9", 30 Ekim - 03 Kasım 2016
- XXVIII. **Pharmacogenomics and Pharmacomicrobiomics in Precision Medicine**  
SÜSLEYİCİ DUMAN B.  
24th Meeting of Balkan Clinical Laboratory Federation 4th Albanian National Conference of Laboratory Medicine, Arnavutluk, 5 - 07 Ekim 2016
- XXIX. **Personalized Medicine Pharmacotherapy Pharmacogenetics**  
SÜSLEYİCİ DUMAN B.  
International Conference on Science and Technology, Türkiye, 3 - 06 Ekim 2016
- XXX. **Yeni Teknolojiler Işığında Bireye Özgü İlaç Tedaviler Farmokogenetik Yaklaşım**  
SÜSLEYİCİ DUMAN B.  
GLAB Açılış Toplantısı, Türkiye, 26 Eylül 2016
- XXXI. **Implementation of Pharmacogenomics in Turkey**  
SÜSLEYİCİ DUMAN B.  
3rd ESPT Summer School, 20 - 25 Ağustos 2016
- XXXII. **Investigatio of Gain Loss Deletion of Genomic Copy Number Variant in Children with Non syndromic Supernumerary Teeth**  
MENTEŞ A. R., PEKER B., ÇEVİK M., KOLDEMİR GÜNDÜZ M., SÜSLEYİCİ DUMAN B.  
Tooth Morphogenesis & Differentiation 2016 - Road to Finland, 13 - 18 Haziran 2016
- XXXIII. **Obezite İlişkili Hastalıkların Bireye Özgü Tedavisinde Yeni Boyut Farmakogenetik**  
SÜSLEYİCİ DUMAN B.  
ULUSAL MOLEKÜLER TIP SEMPOZYUMU, Türkiye, 1 - 03 Haziran 2016
- XXXIV. **Innovations in Pharmacogenomics and Individualized Treatments**  
SÜSLEYİCİ DUMAN B.  
Tıpta İnovasyon Buluşmaları-2, Gaziantep, Türkiye, 5 - 07 Mayıs 2016
- XXXV. **The Effects of Oral Antidiabetic Drug Metformin on Liver Metabolism by Real Time Cell Monitoring System**  
KOLDEMİR GÜNDÜZ M., ZENGİN S. Ü., TAŞKIN M., SÜSLEYİCİ DUMAN B.  
20th WORLD CONGRESS OF THE IFSO, Avusturya, 1 - 02 Mayıs 2016
- XXXVI. **Öngörüşel Tıp Uygulamasında Farmakogenetik**

SÜSLEYİCİ DUMAN B.

XII İÜGEN Uluslararası Katılımlı Moleküler Biyoloji ve Genetik Kış Okulu, 4 - 06 Mart 2016

- XXXVII. **Effects of Fluoxetine HCl on AML 12 Hepatocytes Proliferation by iCELLigence System**  
KOLDEMİR GÜNDÜZ M., ÇEVİK M., KAYMAK G., TARTAR Ş., ESMER H. E., KAYHAN F. E., SÜSLEYİCİ DUMAN B.  
2nd IVEK International Convention of Pharmaceuticals and Pharmacies, İstanbul, Türkiye, 27 - 29 Kasım 2015
- XXXVIII. **Is mesenchymal stem cell therapy suitable for reducing insulin resistance in fructose induced metabolic syndrome rat model**  
BEYHAN ÖZDAŞ Ş., AKIN D., DEMİRCAN G., YAPIŞLAR H., KETENCİ S., KOLDEMİR GÜNDÜZ M., ÇEVİK M., ÇİFTÇİ Ç., SÜSLEYİCİ DUMAN B.  
1st Pharmacogenomics İstanbul Summit: Increasing the Safety and Effectiveness of Personalized therapy for Metabolic Disorders, Türkiye, 27 - 28 Kasım 2015
- XXXIX. **The effects of stem cell therapy on CD68 FTO and RAN expression in fructose induced metabolic syndrome rat model for personalized therapy**  
KOLDEMİR GÜNDÜZ M., ÇEVİK M., AKIN D., BEYHAN ÖZDAŞ Ş., DEMİRCAN G., ÇİFTÇİ Ç., SÜSLEYİCİ DUMAN B.  
1st Pharmacogenomics İstanbul Summit: Increasing the Safety and Effectiveness of Personalized therapy for Metabolic Disorders, Türkiye, 27 - 28 Kasım 2015
- XL. **The role of Apolipoprotein B polymorphisms in essential hypertension**  
ÇEVİK M., KOLDEMİR GÜNDÜZ M., ÇAĞATAY P., ÇİFTÇİ Ç., SÜSLEYİCİ DUMAN B.  
1st Pharmacogenomics İstanbul Summit: Increasing the Safety and Effectiveness of Personalized therapy for Metabolic Disorders, Türkiye, 27 - 28 Kasım 2015
- XLI. **The effects of cytotoxic agents over NIBAN gene expression and 3T3 L1 adipocyte proliferation**  
ÇEVİK M., KOLDEMİR GÜNDÜZ M., SÜSLEYİCİ DUMAN B.  
3rd ESPT Conference. Integration of Pharmacogenomics in Clinical Decision Support, Macaristan, 7 - 09 Ekim 2015
- XLII. **The effects of glipizide on adipogenesis related gene expressions by using impedance cell based label free technology in mature adipocytes**  
KOLDEMİR GÜNDÜZ M., SÜSLEYİCİ DUMAN B.  
3rd ESPT Conference. Integration of Pharmacogenomics in Clinical Decision Support, Macaristan, 7 - 09 Ekim 2015
- XLIII. **The effects of oral antidiabetic drug metformin on liver metabolism by real time cell monitoring system**  
KOLDEMİR GÜNDÜZ M., ZENGİN S. Ü., TAŞKIN M., SÜSLEYİCİ DUMAN B.  
IFSO 20th World Congress. 20th World Congress of International Federation for the Surgery of Obesity & Metabolic Disorders, Avusturya, 26 - 29 Ağustos 2015
- XLIV. **The Effects of Oxidative Stress Agents on FTO and CD68 gene expressions and free radical production in 3T3 L1 Adipocytes**  
KOLDEMİR GÜNDÜZ M., ÇEVİK M., ÇAĞATAY P., AYDIN A., SÜSLEYİCİ DUMAN B.  
International Symposium on Advances in Predictive and Personalized Medicine "Bridging Nations in Istanbul: Personalized and Predictive Medicine in Turkey, Türkiye, 2 - 03 Nisan 2015
- XLV. **The effects of oral antidiabetic drug glipizide on liver metabolism by real time cell monitoring system**  
KOLDEMİR GÜNDÜZ M., SÜSLEYİCİ DUMAN B.  
International Symposium on Advances in Predictive and Personalized Medicine "Bridging Nations in Istanbul: Personalized and Predictive Medicine in Turkey, Türkiye, 2 - 03 Nisan 2015
- XLVI. **Association of endothelial nitric oxide synthase promoter region T 786C gene polymorphism with acute coronary syndrome and coronary heart disease**  
ÇİFTÇİ Ç., MELİL S., ÇEBİ Y., ERSÖZ M., ÇAĞATAY P., KILIÇGEDİK M., SÜSLEYİCİ DUMAN B.  
Lipids in Health and Disease, 15 Eylül 2028 - 18 Eylül 2027, cilt.7

## Desteklenen Projeler

Süsleyici B., Akdeniz C. S., Karaalp A., Yurdakul S., Çevik M., Çiftçi Ç., Diğer Özel Kurumlarca Desteklenen Proje, Design of

antidotes to prevent plaque formation in primary cultures of diabetic patients with coronary atherosclerosis and investigation of therapeutic effects, 2022 - 2024

Süsleyici B., Çevik M., Diğer Resmi Kurumlarca Desteklenen Proje, INVESTIGATION OF MOLECULAR BACKGROUND DIFFERENCES IN METASTASIS FORMATION AND THERAPEUTIC RESPONSE IN PATIENTS WITH COLORECTAL ADENOCARCINOMA, 2018 - 2022

Süsleyici B., CB Strateji ve Bütçe Başkanlığı (Kalkınma Bakanlığı) Projesi, Strategic Pharmacogenetics Project for Individualized Rational Drug Use in Turkey, 2017 - 2018

Süsleyici B., Oda/Sendika/Meslek Birliği, 8. The Roles of Adipocyte and Macrophage Products and/or the Proteomes They Secrete in the Pathogenesis of Metabolic Syndrome. Approach in Terms of Molecular Genetics, 2004 - 2005

Süsleyici B., AB Destekli Diğer Projeler, ApoE Genotyping in a Turkish Study Population with NIDDM-postdoc project, 2000 - 2001

## **Metrikler**

Yayın: 101

Atf (WoS): 256

Atf (Scopus): 437

H-İndeks (WoS): 9

H-İndeks (Scopus): 11